ÃÛÌÒÊÓÆµ

Life Sciences

  • June 10, 2025

    House 23andMe Hearing Raises National Security Concerns

    Lawmakers pressed current and former 23andMe executives during a House Oversight Committee hearing Tuesday over national security and consumer privacy in connection with a planned Chapter 11 sale of 15 million customers' DNA profiles.

  • June 10, 2025

    Dog Owner Defends Tick Meds Suit Against Elanco, Retailers

    A consumer plaintiff has urged an Indiana federal judge not to dismiss her proposed class action accusing Elanco Animal Health Inc. of paying off alleged co-conspirators Chewy, Petco, PetMed Express, PetSmart and PetSense to not carry cheaper generative alternatives to the Advantix topical flea and tick pet prevention drugs.

  • June 10, 2025

    Healthcare, Tech-Focused SPAC Prices $220M IPO

    Special purpose acquisition company Blue Water Acquisition Corp. III began trading on the Nasdaq on Tuesday after pricing its $220 million initial public offering.

  • June 10, 2025

    Most M&A Dealmakers Are Targeting AI Acquisitions

    Corporate and private equity dealmakers are rapidly integrating artificial intelligence into their mergers and acquisitions strategies, with 51% having acquired an AI business and 46% planning to do so soon, according to a new Norton Rose Fulbright report.

  • June 10, 2025

    Ayahuasca Church Brings Religious Use Case To DC Circ.

    An Iowa church that seeks to use a psychedelic drug in its rites filed a petition Monday with the D.C. Circuit seeking to compel federal drug enforcers to process an application for a religious exemption to the Controlled Substances Act, which has been pending for over six years.

  • June 10, 2025

    Merck Gets PTAB To Nix Johns Hopkins Cancer Drug Patent

    Merck & Co. Inc. subsidiary Merck Sharp & Dohme LLC has notched a win at the Patent Trial and Appeal Board in its disagreement with Johns Hopkins University over a cancer research partnership, persuading a panel to invalidate claims in a university-owned patent relating to a colorectal cancer treatment.

  • June 10, 2025

    Catching Up With Delaware's Chancery Court

    Delaware's Court of Chancery showed new resistance to suits alleging corporate weaponizing of advance notice bylaws, and a new report highlighted the high fees that attorneys are cashing in on in Delaware courts compared to the federal court system. Several new suits were also filed concerning allegedly under- or overvalued sales and acquisitions being pushed through.

  • June 10, 2025

    Neurocrine Loses Suit Challenging Hormone Treatment Patent

    Neurocrine Biosciences has lost its attempt in Delaware federal court to invalidate a patent owned by biotechnology company Spruce Biosciences Inc. relating to the treatment of a hormonal disorder, after a federal judge tossed the lawsuit.

  • June 10, 2025

    Biopharma Co. Unit Hopes To Shed Empty Facilities In Ch. 11

    A subsidiary of biopharmaceutical manufacturer National Resilience Holdco Inc. filed for Chapter 11 protection Tuesday in Delaware bankruptcy court with a reorganization plan involving shutting down offices, manufacturing sites and labs it described as "underutilized."

  • June 10, 2025

    Reed Smith Int'l Arbitration Pro Jumps To Bracewell In NYC

    Bracewell LLP has added an international arbitration practitioner with more than two decades of BigLaw experience across a range of industries and locations, including most recently as a partner at Reed Smith LLP, to its New York roster, as the firm looks to grow the practice area.

  • June 09, 2025

    Judge To Limit Experts in Biogen, Genentech Drug Royalty Trial

    A California federal judge Monday laid out the ground rules for an upcoming high-stakes jury trial between Biogen and Roche Holding AG subsidiary Genentech over patent royalties on multiple sclerosis drug sales, giving each side nine hours to argue their case and saying she plans to limit expert testimony.

  • June 09, 2025

    Acadia Win On Parkinson's Drug Patent Upheld By Fed. Circ.

    The Federal Circuit on Monday upheld the validity of an Acadia Pharmaceuticals Parkinson's disease drug patent, saying the result was compelled by double-patenting precedent the court set last year, but generics maker MSN Laboratories has suggested it may seek en banc review.

  • June 09, 2025

    RFK Jr. Fires CDC's Entire 17-Member Vaccine Advisory Panel

    The U.S. Department of Health and Human Services announced Monday that Secretary Robert F. Kennedy Jr. removed every member of the committee that provides advice and guidance on the use of vaccines to the Centers for Disease Control and Prevention, pledging to replace them with his preferred picks.

  • June 09, 2025

    Chinese Student Accused Of Smuggling Roundworms To US

    A Chinese student pursuing a doctoral degree in Wuhan has been charged with smuggling roundworms to recipients associated with a University of Michigan laboratory and lying to federal agents about it, according to an announcement Monday by the U.S. Attorney's Office for the Eastern District of Michigan. 

  • June 09, 2025

    Gov't Seeks $706M Penalty In FCA Case Against Omnicare, CVS

    The government asked a New York federal judge to impose a collective $706 million in civil penalties on Omnicare Inc. and its parent, CVS Health Corp., after a jury found that they submitted millions of false billing claims for healthcare programs.

  • June 09, 2025

    Edwards Can't Get Fed. Circ. To Overrule PTAB Amendments

    The Patent Trial and Appeal Board rightly held that amended claims of a Cardiovalve Ltd. heart valve implant aren't invalid, the Federal Circuit affirmed Monday.

  • June 09, 2025

    Investment Firm Lead Admits To Insider Trading Biotech Stock

    The former head of equity trading at Denver-based capital markets firm Irving Investors LLC admitted to receiving insider information on multiple companies and using that nonpublic knowledge to guide trading decisions to make an unlawful $220,912 profit, Connecticut U.S. Attorney David X. Sullivan announced.

  • June 09, 2025

    5th Amendment Can't Shield Ex-Exec, Drugmakers Argue

    Generic-drug makers urged a Pennsylvania court to compel a former executive to sit for a deposition in ongoing price-fixing litigation despite his invocation of the Fifth Amendment, arguing his testimony is crucial to their defense.

  • June 09, 2025

    Fitch Even's Ex-IP Client Wants Firm's Patent Suit Tossed

    Prenatal-Hope Inc. and its chief executive officer are asking an Illinois federal judge to dismiss a suit in which law firm Fitch Even Tabin & Flannery LLP seeks a declaration that the CEO isn't the inventor behind a prenatal test patent.

  • June 09, 2025

    Sheppard Mullin Adds Perkins Coie IP Trio In DC, Chicago

    Three Perkins Coie LLP intellectual property partners with deep experience representing clients in the pharmaceutical, biotechnology and related industries have jumped to Sheppard Mullin Richter & Hampton LLP.

  • June 09, 2025

    AI-Powered Cancer Diagnostics Firm Targets $400M IPO

    Caris Life Sciences Inc., a developer of artificial-intelligence enhanced cancer diagnostic tests, on Monday launched plans for an estimated $400 million initial public offering, represented by Latham & Watkins LLP and underwriters counsel Cooley LLP.

  • June 09, 2025

    HI Gov. Eyes Veto Of Medical Pot Bill Over Privacy Concerns

    Hawaii Gov. Josh Green has signaled that he intends to veto a bill modifying the state's medical marijuana program, saying that it would impinge the privacy rights of the Aloha State's medical cannabis patients.

  • June 09, 2025

    Rite Aid Gets Stay Of Appeals From Its Earlier Bankruptcy

    The New Jersey bankruptcy judge overseeing Rite Aid's current insolvency case pressed pause Monday on appeals of orders he entered last year in the drugstore chain's previous Chapter 11.

  • June 09, 2025

    Legal, Compliance Heads Named In Mallinckrodt-Endo Merger

    Ahead of finalizing their $6.7 billion merger, Ireland's Mallinckrodt PLC and Pennsylvania-based Endo Inc. announced that Mallinckrodt's current chief legal officer and Endo's chief compliance officer will be a part of the executive team that will drive the formation of what the companies said will be a global pharmaceutical industry leader.

  • June 09, 2025

    Husch Blackwell Hires 5 Quarles & Brady Life Sciences Pros

    Amid its efforts to grow in the life sciences space, Husch Blackwell LLP announced Monday that it has brought on three lawyers and two non-attorney professionals from Quarles & Brady LLP.

Expert Analysis

  • Series

    Adapting To Private Practice: From SEC To BigLaw

    Author Photo

    As I adjusted to the multifaceted workflow of a BigLaw firm after leaving the U.S. Securities and Exchange Commission, working side by side with new colleagues on complex matters proved the fastest way to build a deep rapport and demonstrate my value, says Jennifer Lee at Jenner & Block.

  • China High Court Ruling Could Encourage Antitrust Litigation

    Author Photo

    Practitioners defending U.S. companies in China should take note of a Chinese Supreme Court ruling that plaintiffs can file suits based on either where the alleged action, or where the result of such action, occurred — which will promote civil litigation by minimizing procedural battles over forum selection, says Yang Yang at Leaqual Law Firm.

  • Making The Case For Rest In The Legal Profession

    Author Photo

    For too long, a culture of overwork has plagued the legal profession, but research shows that attorneys need rest to perform optimally and sustainably, so legal organizations and individuals must implement strategies that allow for restoration, says Marissa Alert at MDA Wellness, Carol Ross-Burnett at CRB Global, and Denise Robinson at The Still Center.

  • How Amended Rule 702 Affects Testimony In Patent Litigation

    Author Photo

    In 2023, Federal Rule of Evidence 702 was amended to address the apparent failure of some courts to prevent unreliable expert evidence from reaching a jury, but a statistical analysis of Daubert decisions in 2022 and 2024 shows that courts remain divided about how to apply consistent evidence standards, say attorneys at Perkins Coie.

  • What Trump's Order Means For The Legal Status Of IVF

    Author Photo

    An executive order signed by President Donald Trump last month signals the administration's potential intention to increase protections for in vitro fertilization services, though more concrete actions would be needed to resolve the current uncertainty around IVF access or bring about a binding legal change, says Jeanne Vance at Weintraub Tobin.

  • Mitigating Tariff Risks For Healthcare In US And Canada

    Author Photo

    Healthcare stakeholders should take steps to evaluate the impact of cross-border tariffs, as the historically strong ties between Canada and the U.S. demonstrate the potential for real disruption and harm to the healthcare industry in both countries, say attorneys at Norton Rose.

  • 4 Ways Women Attorneys Can Build A Legal Legacy

    Author Photo

    This Women’s History Month, women attorneys should consider what small, day-to-day actions they can take to help leave a lasting impact for future generations, even if it means mentoring one person or taking 10 minutes to make a plan, says Jackie Prester, a former shareholder at Baker Donelson.

  • A Judge's Pointers For Adding Spice To Dry Legal Writing

    Author Photo

    U.S. District Judge Fred Biery shares a few key lessons about how to go against the grain of the legal writing tradition by adding color to bland judicial opinions, such as by telling a human story and injecting literary devices where possible.

  • Preparing For Disruptions To Life Sciences Supply Chains

    Author Photo

    Life sciences companies must assess how new and escalating tariffs — combined with other restrictions on cross-border activity singling out pharmaceutical products and medical devices — will affect supply chains, and they should proactively prepare for antitrust and foreign direct investment regulatory review processes, say attorneys at Weil.

  • Mastering The Fundamentals Of Life Sciences Due Diligence

    Author Photo

    As life sciences transactions continue to gain tremendous momentum, companies participating in these transactions must conduct effective and strategic regulatory due diligence, which involves extensive amounts of information and varies by manifold factors, says Anna Zhao at GunnerCooke.

  • Beware Risks Of Arguing Multiple Constructions In IP Cases

    Author Photo

    Defendants accused of patent infringement often argue for different, potentially contradictory, claim constructions before district courts and the Patent Trial and Appeal Board, but the board may be clamping down on this strategy, say attorneys at Dechert.

  • What's At Stake In High Court Transgender Care Suit

    Author Photo

    The outcome of U.S. v. Skrmetti will have critical implications for the rights of transgender youth and their access to gender-affirming care, and will likely affect other areas of law and policy involving transgender individuals, including education, employment, healthcare and civil rights, say attorneys at ArentFox Schiff.

  • 6th Circ. Ruling Paves Path Out Of Loper Bright 'Twilight Zone'

    Author Photo

    The U.S. Supreme Court’s Loper Bright ruling created a twilight zone between express statutory delegations that trigger agency deference and implicit ones that do not, but the Sixth Circuit’s recent ruling in Moctezuma-Reyes v. Garland crafted a two-part test for resolving cases within this gray area, say attorneys at Wiley.

  • A Reminder On Avoiding Improper Venues In Patent Cases

    Author Photo

    A Texas federal court's recent decision in the Symbology and Quantum cases shows that baseless patent venue allegations may be subject to serious Rule 11 sanctions, providing venue-vetting takeaways for plaintiffs and defendants, say attorneys at Bond Schoeneck.

  • NIH Cuts To Indirect Costs May Stifle IP Generation

    Author Photo

    Although currently blocked by a preliminary injunction, the National Institutes of Health's new policy to cut down on indirect cost funding creates challenges for university research projects, and may hamper the development of intellectual property — which is considered an indirect cost — for years to come, say attorneys at Snell & Wilmer.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.